Dr. Lorenzo Guglielmetti Named to TIME100 List
Recognized for advancements in treating TB.
Posted on May 19, 2025
Dr. Lorenzo Guglielmetti, co-principal investigator of the endTB clinical trials, has been named to the 2025 TIME100 Health list, which honors the most influential people driving innovation in global health and medicine.
Each year, TIME100 recognizes individuals making a significant impact through their work. Guglielmetti’s inclusion underscores his leadership in the fight against tuberculosis (TB), the world’s deadliest infectious disease.
“I am deeply honored to be part of this extraordinary group of individuals,” Guglielmetti said. “This recognition is not only for me but for the entire endTB team and the patients we work to help. It’s a call to action to continue advancing scientific research and to ensure that no one is left behind in the fight against TB.”
His selection draws attention to the urgent need for innovation in global health, especially amid rising rates of drug-resistant disease and declining investment in public health.
This recognition also acknowledges the groundbreaking work of the endTB project—a global partnership led by Médecins Sans Frontières, Partners In Health, Interactive Research and Development, and Harvard Medical School. Active in 18 countries, the project aims to provide shorter, less toxic, and more effective treatment for multidrug-resistant tuberculosis (MDR-TB)—a notoriously grueling form of the disease—through cutting-edge research and policy advocacy.
Throughout his career, Guglielmetti has focused on developing treatment regimens that reduce side effects and treatment duration while expanding access for patients. He has authored more than 70 peer-reviewed articles on TB and mycobacterial infections. In 2025, Guglielmetti served as lead author of a landmark study in The New England Journal of Medicine that helped establish new oral drug regimens to treat rifampin-resistant TB.
Research projects have taken Guglielmetti to countries heavily impacted by TB, including Georgia and regions of Central Asia. He currently holds positions at the National Reference Center for Mycobacteria and at Sorbonne University in Paris, where he continues to champion scientific collaboration and patient-centered care.
Guglielmetti’s inclusion on the TIME100 list is not only a personal achievement but a testament to the global effort to eliminate TB. As the world confronts growing threats to public health, the recognition serves as a reminder of what can be achieved through collective action and scientific advancement.
With continued support from global health leaders and organizations, the fight against TB will keep gaining momentum—pushing relentlessly toward a healthier and more equitable future for all.
To learn more about Dr. Lorenzo Guglielmetti and his work, visit the endTB website, and read the full 2025 TIME100 Health list.
